

## Hypertension 2020 – Market Analysis

**Eman Anwar Diab**

Alexandria University, Egypt, E-mail: [Emananwar1@gmail.com](mailto:Emananwar1@gmail.com)

Hypertension (AI) that provides systems the ability to automatically learn and improve from experience without being explicitly programmed. Deep Learning focuses on the development of computer programs that can access data and use it learn for themselves. The process of learning begins with observations or data, such as examples, direct experience, or instruction, in order to look for patterns in data and make better decisions in the future based on the examples that we provide. The primary aim is to allow the computers learn automatically without human intervention or assistance and adjust actions accordingly.

Healthcare enables analysis of massive quantities of data. While it generally delivers faster, more accurate results in order to identify profitable opportunities or dangerous risks, it may also require additional time and resources to train it properly. Combining Deep Learning with AI and cognitive technologies can make it even more effective in processing large volumes of information. The aim of the Artificial Intelligence is to build new and/or leverage existing algorithms to learn from data, in order to build generalizable models that give accurate predictions, or to find patterns, particularly with new and unseen similar data.


As per a statement of World Health Organization (WHO), Hypertension is one of the silent killers in 21st century and is one of the biggest global public health concerns. Hypertension is major contributors of cardiac complications, stroke, heart diseases, kidney failure, blindness, including premature death and disabilities. Hypertension is curable as well as treatable for which there is a need of involvement from individual entities, government and private sectors, health workers, civil societies and moreover individual awareness is highly recommended.

As per the estimation of WHO, globally more than 1.13 billion of people are affected with Hypertension among which less than 1 in each 5 is under control. Unhealthy diets, lack of physical activities, consumption of alcohol & tobacco are the main contributing factors of Hypertension. To reduce the prevalence by 25% by 2025, WHO along with United States Center for Disease Control and Prevention launched Global heart Initiative in 2016. Globally, Hypertension or high Blood Pressure leads to 7.5million death cases which shares about 12.8% of all

death cases recorded. Hypertension is also accounts about 57million disabilities adjusted life years which is about 3.7% of total adjusted life years. Hypertension is the primary risk factor of coronary heart disease, ischemic & haemorrhagic stroke.

Global prevalence of Hypertension in adult aged>25 was about 40% in 2008. Between 1980 to 2008 the prevalence was moderate. But, due to sharp growth in population, ageing population the uncontrolled Hypertension reached to 1 billion 2008 from 600 million. The prevalence of Hypertension was highest in Africa (>40%) and lower in Americas (35%).


### Overall Prevalence of Hypertension Globally



As per the research of some independent firm, global Hypertension drug market is estimated to be \$24.7billion in 2018 & expected to hit about \$19.3 billion by 2029 with an annual CAGR of -2.3% in between 2019 to 2029.

Main Drugs in the Hypertension market are Tacleer, Uptravi, Opsumit, Letairis, Adcirca, Revatio, Adempas, Veletri, Oremitram, Tyvaso, Remodulin. Major classes of drugs used are: Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, and Renin Inhibitors. Major players in the anti-hypertensive drugs market are: Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Sanofi Aventis and United Therapeutics.

### Hypertension Associations World Wide



As per another survey, global Pulmonary Arterial Hypertension (PAH) market is forecasted to touch \$9.3 billion by 2026 with an CAGR of 5.6% during 2019-2026. Rising cases of PAH and the support from federal Government and private organizations, development of Orphan Drug products for PAH is fuelling the growth of the market.

According to Statistics MRC, the Global Stroke Diagnostics and Therapeutics market is reckoned for \$23,849.39 Million in 2017 and is estimated to reach \$49,698.68 Million by 2026 growing at a CAGR of 8.5% during the forecast period.

Factors like technological advancement, a growing aging population, and people affected by diabetes, high blood pressure are favouring the market. On the other hand, increasing health expenditure, cardiovascular diseases and increasing tobacco users are supplying the market.

Hypertension is a chronic medical condition during which the blood pressure is elevated to an unsought level. Hypertension is a chronic disease, which means that a patient could need to require medications a day for the rest of his/her life. Thus, the demand for anti-hypertensive medication is property and can increase with a rise within the variety of target patients. Anti-hypertensive drugs were the second largest therapy area in 2011 with the worldwide sales worth of over USD 40 billion, according to the globe Preview 2018 report by valuate drug company.

Some of the key players contributing to the worldwide anti-hypertensive medication market include Novartis AG, Pfizer, Inc., Johnson & Johnson Ltd., Sanofi S.A., Lupin Limited, Ranbaxy Laboratories Limited, Merck & Co., Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, and Takeda Pharmaceutical Company Limited.

This research report analyses this market counting on its market segments, major geographies, and current market trends. Geographies analysed under this analysis report include

- North America
- Asia Pacific
- Europe
- Rest of the World

We are happy to announce our next conference “8th International Conference on Hypertension and Healthcare” Congress which is scheduled in August 10-11, 2020 Dubai, UAE.

#### Organizing Committee Members:

1. Wei Ling Huang, Medical Research, Medical Acupuncture and Pain Management Clinic, Brazil.
2. Eman Anwar Diab, Alexandria Faculty of Medicine, Egypt.

Contact:

William Luther

Program Manager | Hypertension cardiology 2020

47 Church field Road

London, W3 6AY, United Kingdom